Quantbot Technologies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Quantbot Technologies’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-561	Closed	-$4K	–	2180
2021 Q4	$4K	Sell	561 -500	-47%	-$4.12K	﹤0.01%	1404
2021 Q3	$7K	Sell	1,061 -1,100	-51%	-$6.81K	﹤0.01%	1391
2021 Q2	$14K	Buy	2,161 +1,800	+499%	+$15K	﹤0.01%	1272
2021 Q1	$3K	Buy	+361	New	+$3.95K	﹤0.01%	1333
2018 Q2	–	Sell	-2,861	Closed	-$63K	–	1575
2018 Q1	$63K	Buy	+2,861	New	+$63.5K	0.01%	947

Other funds holding JNCE

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Quantbot Technologies's JNCE Position: Q1 2022 in Review

Quantbot Technologies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 561 shares — an estimated $4K sold.

Quantbot Technologies first reported a position in JNCE in Q1 2018 and held it in 5 quarters. The position peaked at $63K in Q1 2018. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

Quantbot Technologies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Quantbot Technologies sold 561 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $4K.
Quantbot Technologies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Quantbot Technologies's Jounce Therapeutics, Inc. Common Stock position peaked at $63K in Q1 2018.
113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Quantbot Technologies's 13F filing for Q1 2022, filed 16 May 2022.